GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• GPRC5A (G protein-coupled receptor, class C, group 5, member A) is a retinoic acid-induced gene highly expressed in lung tissue.
• Gprc5a gene deletion in mice results in spontaneous lung tumor formation, indicating a tumor-suppressive role.
• The precise molecular mechanisms underlying GPRC5A's tumor suppression in the lung remain largely unelucidated.

Purpose of the Study:

• To investigate the role of GPRC5A in lung tumorigenesis.
• To elucidate the molecular pathways involved in GPRC5A-deficient lung tumor development.
• To explore potential therapeutic targets for lung cancer based on GPRC5A's function.

Main Methods:

• Comparison of Gprc5a-knockout (ko) mouse tracheal epithelial cells (KO-MTEC) with wild-type cells.
• Inhibition of MDM2 (mouse double minute 2 homolog) using Nutlin-3a or small hairpin RNA (sh-RNA) in lung cancer cell lines.
• Targeting EGFR (epidermal growth factor receptor) signaling using Erlotinib or sh-RNA.
• Analysis of GPRC5A and MDM2 expression in clinical human lung cancer tissues.

Main Results:

• MDM2, a negative regulator of p53, was found to be dysregulated in Gprc5a-ko cells.
• Targeting MDM2 restored the p53 signaling pathway, reduced cancer stem cell markers, and inhibited tumorigenicity in Gprc5a-ko derived and human lung cancer cells.
• Activated EGFR signaling stabilized MDM2 in a transcription-independent manner.
• Overexpression of MDM2 and reduced GPRC5A expression were observed in human lung cancer tissues.

Conclusions:

• Dysregulated MDM2 is crucial for the oncogenic activity in GPRC5A-deficient lung cancer cells.
• EGFR signaling plays a key role in stabilizing MDM2, contributing to lung tumor development.
• GPRC5A deficiency promotes lung tumorigenesis by leading to MDM2 dysregulation via activated EGFR signaling, highlighting a novel mechanism in lung cancer pathogenesis.